Genetically modified tumour vaccines: Insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene

International Journal of Oncology

Volumn 10, Issue 1, 1997, Pages 77-82

  Rössner, Pavel ^a   Bubeník, Jan ^a   Indrová, Marie ^a   Sobota, Vesna ^a   Vondrys, Pavel ^a   Zeuthen, Jesper ^b   Jandlová, Tána ^a   Takác, Mirko ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

IL 2 and CD80 genes; Murine sarcoma; Transfection; Tumorigenicity

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031027907     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bubeník J, Voitenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubeníková D, Símová J and Jandlová T: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 19: 279-282, 1988.
2. Bubeník J: IL-2 and gene therapy of cancer (Review). Int J Oncol 2: 1049-1052, 1993.
3. Bubeník J: Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther 69: 1-14, 1996.
4. Bubeník J, Indrová M, Nemeeková S, Malkovsky M, Von Broen B, Pálek V, Anderlíková J: Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, and transplantantion tests. Int J Cancer 21: 348-355, 1978.
5. Karasuyama H and Melchers F: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 18: 97-104, 1988.
6. Gillis S, Smith KA: Long-term culture of tumour-specific cytotoxic T cells. Nature 268: 154-156, 1977.
7. Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factor: parameters of production and quantitative microassay for activity. J Immunol 120: 2027-2032, 1978.
8. Smith KA: T cell growth factor. Immunol Rev 51: 337-357, 1980.
9. Smith KA: Continuous cytotoxic T-cell lines. In: Contemporary Topics in Immunobiology. Warner NL (ed.) Plenum Press, New York, pp139-155, 1980.
10. Bubeník J, Indrová M, Símová J, Kypenová H, Bubeníková D, Dolezalová K: Phorbol myristate acetate-stimulated production of interleukin 2 by T cell lymphoma and constitutive production by derived hybridomas. Neoplasma 31: 497-505, 1984.
11. Bubeník J, Indrová M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcová A: Tumour inhibitory effect of TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 19: 57-61, 1985.
12. El-Ghazali GEB, Paulie S, Anderson G, Hansson Y, Holmquist G, Sun J-B, Ekre HP, Troye-Blomberg M: Number of interleukin-4-and interferon-γ-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profile depending on the type of antigen used for activation. Eur J Immunol 23: 2740-2745, 1993.
13. Julius MH, Simpson E, Herzenberg LA: A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3: 645-649, 1973.
14. Trizio D, Cudkowitz G: Separation of T and B lymphocytes by nylon wool columns: Evaluation of efficacy by functional assay in vivo. J Immunol 113: 1093-1097, 1974.
15. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumour immune responses induced by B7-transfected tumours. Cancer Res 54: 6477-6483, 1994.
16. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ: Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87: 2938-2946, 1996.
17. Turcovski-Corrales SM, Fenton RG, Peltz G and Taub DD: CD28:B7 interactions promote T cell adhesion. Eur J Immunol 25: 3087-3093, 1995.
18. Bubenik J: Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Folia Biol (Praha) 42: 295-304, 1996.
19. Takác M, Cerná J, Habrová V, Stokrová J, Rychlík I, Jonák J: Microinjection of cloned proviral Rous sarcoma virus DNAs into Xenopus laevis one cell embryos. Folia Biol (Praha) 38: 65-77, 1992.